Acute Heart Failure Clinical Trial
— REPORT-HFOfficial title:
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
| NCT number | NCT02595814 |
| Other study ID # | CRPORTHF |
| Secondary ID | |
| Status | Terminated |
| Phase | |
| First received | |
| Last updated | |
| Start date | July 23, 2014 |
| Est. completion date | March 31, 2018 |
| Verified date | November 2018 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.
| Status | Terminated |
| Enrollment | 18805 |
| Est. completion date | March 31, 2018 |
| Est. primary completion date | March 31, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure. Exclusion Criteria: 1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor). 2. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. |
| Country | Name | City | State |
|---|---|---|---|
| Algeria | Novartis Investigative Site | Algiers | |
| Algeria | Novartis Investigative Site | Algiers | |
| Algeria | Novartis Investigative Site | Algiers | |
| Algeria | Novartis Investigative Site | Oran | |
| Argentina | Novartis Investigative Site | Buenos Aires | |
| Argentina | Novartis Investigative Site | Buenos Aires | |
| Argentina | Novartis Investigative Site | Buenos Aires | |
| Argentina | Novartis Investigative Site | Buenos Aires | Ciudad De Buenos Aires |
| Argentina | Novartis Investigative Site | Caba | Buenos Aires |
| Argentina | Novartis Investigative Site | Caba | Buenos Aires |
| Argentina | Novartis Investigative Site | Cordoba | |
| Argentina | Novartis Investigative Site | Cordoba | |
| Argentina | Novartis Investigative Site | Coronel Suarez | Ciudad De Buenos Aires |
| Argentina | Novartis Investigative Site | Corrientes | |
| Argentina | Novartis Investigative Site | Mendoza | |
| Argentina | Novartis Investigative Site | Resistencia | Chaco |
| Argentina | Novartis Investigative Site | Rosario | Santa Fe |
| Argentina | Novartis Investigative Site | Rosario | Santa Fe |
| Argentina | Novartis Investigative Site | Salta | |
| Australia | Novartis Investigative Site | Auchenflower | Queensland |
| Australia | Novartis Investigative Site | Bedford Park | |
| Australia | Novartis Investigative Site | Gosford | New South Wales |
| Australia | Novartis Investigative Site | Greenslopes | Queensland |
| Austria | Novartis Investigative Site | Eisenstadt | |
| Austria | Novartis Investigative Site | Linz | |
| Austria | Novartis Investigative Site | Moedling | |
| Austria | Novartis Investigative Site | Vienna | |
| Austria | Novartis Investigative Site | Wien | |
| Brazil | Novartis Investigative Site | Belo Horizonte | MG |
| Brazil | Novartis Investigative Site | Campinas | SP |
| Brazil | Novartis Investigative Site | Curitiba | PR |
| Brazil | Novartis Investigative Site | Curitiba | |
| Brazil | Novartis Investigative Site | Fortaleza | CE |
| Brazil | Novartis Investigative Site | Recife | |
| Brazil | Novartis Investigative Site | Rio De Janeiro | |
| Brazil | Novartis Investigative Site | Rio de Janeiro | RJ |
| Brazil | Novartis Investigative Site | Sao Jose Do Rico Preto | |
| Brazil | Novartis Investigative Site | Tatuí | SP |
| Bulgaria | Novartis Investigative Site | Pleven | |
| Bulgaria | Novartis Investigative Site | Plovdiv | |
| Bulgaria | Novartis Investigative Site | Sofia | |
| Bulgaria | Novartis Investigative Site | Sofia | |
| Bulgaria | Novartis Investigative Site | Sofia | |
| Bulgaria | Novartis Investigative Site | Varna | |
| Canada | Novartis Investigative Site | Edmonton | Alberta |
| Canada | Novartis Investigative Site | Halifax | Nova Scotia |
| Canada | Novartis Investigative Site | Ottawa | Ontario |
| Canada | Novartis Investigative Site | Sainte-Foy | Quebec |
| Canada | Novartis Investigative Site | Vancouver | British Columbia |
| Chile | Novartis Investigative Site | Concepcion | |
| Chile | Novartis Investigative Site | San Miguel | Santiago |
| Chile | Novartis Investigative Site | Santiago | |
| Chile | Novartis Investigative Site | Santiago | |
| China | Novartis Investigative Site | Baotou | Inner Mongolia |
| China | Novartis Investigative Site | Beijing | Beijing |
| China | Novartis Investigative Site | Beijing | Beijing |
| China | Novartis Investigative Site | Beijing | |
| China | Novartis Investigative Site | Beijing | |
| China | Novartis Investigative Site | Beijing | |
| China | Novartis Investigative Site | Beijing | |
| China | Novartis Investigative Site | Beijing | |
| China | Novartis Investigative Site | Changchun | Jilin |
| China | Novartis Investigative Site | Changsha | Hunan |
| China | Novartis Investigative Site | Changsha | Hunan |
| China | Novartis Investigative Site | Dalian | Liaoning |
| China | Novartis Investigative Site | Fuzhou | Fujian |
| China | Novartis Investigative Site | Guang Zhou | |
| China | Novartis Investigative Site | Guangzhou | Guangdong |
| China | Novartis Investigative Site | Hangzhou | |
| China | Novartis Investigative Site | Jinan | |
| China | Novartis Investigative Site | Luoyang | |
| China | Novartis Investigative Site | Shanghai | |
| China | Novartis Investigative Site | Shijiazhuang | Hebei |
| China | Novartis Investigative Site | Taiyuan | |
| China | Novartis Investigative Site | Urumqi | |
| China | Novartis Investigative Site | Urumqi | |
| China | Novartis Investigative Site | Wuhan | |
| China | Novartis Investigative Site | Wuhan | Hubei |
| China | Novartis Investigative Site | Xiamen | |
| China | Novartis Investigative Site | Yangzhou | |
| China | Novartis Investigative Site | Zhengzhou | |
| China | Novartis Investigative Site | Zhengzhou | |
| Colombia | Novartis Investigative Site | Armenia | |
| Colombia | Novartis Investigative Site | Barranquilla | Atlantico |
| Colombia | Novartis Investigative Site | Barranquilla | Atlántico |
| Colombia | Novartis Investigative Site | Bogota | |
| Colombia | Novartis Investigative Site | Bogotá | |
| Colombia | Novartis Investigative Site | Bogotá | |
| Colombia | Novartis Investigative Site | Bogotá | Cundinamarca |
| Colombia | Novartis Investigative Site | Bucaramanga | Santander |
| Colombia | Novartis Investigative Site | Cali | |
| Colombia | Novartis Investigative Site | Medellin | Antioquia |
| Colombia | Novartis Investigative Site | Medellin | Antioquia |
| Ecuador | Novartis Investigative Site | Guayaquil | Guayas |
| Ecuador | Novartis Investigative Site | Guayaquil | |
| Ecuador | Novartis Investigative Site | Portoviejo | |
| Ecuador | Novartis Investigative Site | Quito | Pichincha |
| Egypt | Novartis Investigative Site | Alexandria | |
| Egypt | Novartis Investigative Site | Cairo | |
| Egypt | Novartis Investigative Site | Cairo | |
| Egypt | Novartis Investigative Site | El Menia, Upper Egypt | |
| Egypt | Novartis Investigative Site | Suez Canal Region | |
| Germany | Novartis Investigative Site | Berlin | |
| Germany | Novartis Investigative Site | Bonn | |
| Germany | Novartis Investigative Site | Essen | |
| Germany | Novartis Investigative Site | Freiburg | |
| Germany | Novartis Investigative Site | Goettingen | |
| Germany | Novartis Investigative Site | Halle | |
| Germany | Novartis Investigative Site | Hannover | |
| Germany | Novartis Investigative Site | Heidelberg | |
| Germany | Novartis Investigative Site | Homburg | |
| Germany | Novartis Investigative Site | Lubeck | |
| Germany | Novartis Investigative Site | Ludwigshafen | |
| Germany | Novartis Investigative Site | Nürnberg | |
| Germany | Novartis Investigative Site | Wurzburg | |
| Greece | Novartis Investigative Site | Athens | GR |
| Greece | Novartis Investigative Site | Athens | GR |
| Greece | Novartis Investigative Site | Athens | GR |
| Greece | Novartis Investigative Site | Athens | |
| Greece | Novartis Investigative Site | Athens | |
| Greece | Novartis Investigative Site | Athens | |
| Greece | Novartis Investigative Site | Glyfada | |
| Greece | Novartis Investigative Site | Ioannina | |
| Greece | Novartis Investigative Site | Piraeus | |
| Greece | Novartis Investigative Site | Thessaloniki | |
| Greece | Novartis Investigative Site | Thessaloniki | GR |
| Guatemala | Novartis Investigative Site | Guatemala | |
| Guatemala | Novartis Investigative Site | Guatemala | |
| Guatemala | Novartis Investigative Site | Guatemala City | |
| India | Novartis Investigative Site | Ahmedabad | Gujarat |
| India | Novartis Investigative Site | Amritsar | Punjab |
| India | Novartis Investigative Site | Bangalore | Karnataka |
| India | Novartis Investigative Site | Bangalore | Karnataka |
| India | Novartis Investigative Site | Chennai | Tamil NADU |
| India | Novartis Investigative Site | Gurgaon | Haryana |
| India | Novartis Investigative Site | Hyderabad | Telangana |
| India | Novartis Investigative Site | Hyderabad | Telangana |
| India | Novartis Investigative Site | India | |
| India | Novartis Investigative Site | Kolkata | West Bengal |
| India | Novartis Investigative Site | Kolkata | West Bengal |
| India | Novartis Investigative Site | Ludhiana | Punjab |
| India | Novartis Investigative Site | Ludhiana | Punjab |
| India | Novartis Investigative Site | Manipal | Karnataka |
| India | Novartis Investigative Site | Mumbai | |
| India | Novartis Investigative Site | Nagpur | Maharashtra |
| India | Novartis Investigative Site | New Delhi | Delhi |
| India | Novartis Investigative Site | New Delhi | Delhi |
| India | Novartis Investigative Site | New Delhi | Delhi |
| India | Novartis Investigative Site | New Delhi | |
| India | Novartis Investigative Site | New Delhi | |
| India | Novartis Investigative Site | Panaji | Goa |
| India | Novartis Investigative Site | Pune | Maharashtra |
| India | Novartis Investigative Site | Pune | Maharashtra |
| India | Novartis Investigative Site | Vadodara | Gujarat |
| Indonesia | Novartis Investigative Site | Bandung | West Java |
| Indonesia | Novartis Investigative Site | Bekasi | West Java |
| Indonesia | Novartis Investigative Site | East Jakarta | DKI Jakarta |
| Indonesia | Novartis Investigative Site | Medan | North Sumatera |
| Indonesia | Novartis Investigative Site | Padang | Sumatera Barat |
| Indonesia | Novartis Investigative Site | South Jakarta | DKI Jakarta |
| Indonesia | Novartis Investigative Site | Surabaya | East Java |
| Indonesia | Novartis Investigative Site | Tangerang | Banten |
| Indonesia | Novartis Investigative Site | West Jakarta | DKI Jakarta |
| Israel | Novartis Investigative Site | Jerusalem | |
| Israel | Novartis Investigative Site | Jerusalem | |
| Israel | Novartis Investigative Site | Kfar-Saba | |
| Israel | Novartis Investigative Site | Nazareth | |
| Israel | Novartis Investigative Site | Sefad | |
| Japan | Novartis Investigative Site | Chiyoda-ku | Tokyo |
| Japan | Novartis Investigative Site | Hirakata-City | Osaka |
| Japan | Novartis Investigative Site | Kita-ku | Okayama |
| Japan | Novartis Investigative Site | Kitakyushu-city | Fukuoka |
| Japan | Novartis Investigative Site | Kure | Hiroshima |
| Japan | Novartis Investigative Site | Nagasaki | |
| Japan | Novartis Investigative Site | Sakaide-city | Kagawa |
| Jordan | Novartis Investigative Site | Amman | |
| Jordan | Novartis Investigative Site | Amman | |
| Jordan | Novartis Investigative Site | Amman | |
| Jordan | Novartis Investigative Site | Amman | |
| Jordan | Novartis Investigative Site | Irbid | |
| Korea, Republic of | Novartis Investigative Site | Busan | |
| Korea, Republic of | Novartis Investigative Site | Cheongju-si | Chungcheongbuk-do |
| Korea, Republic of | Novartis Investigative Site | Daejeon | Korea |
| Korea, Republic of | Novartis Investigative Site | Gyeonggi-do | Bucheon-si |
| Korea, Republic of | Novartis Investigative Site | Incheon | |
| Korea, Republic of | Novartis Investigative Site | Pusan | |
| Korea, Republic of | Novartis Investigative Site | Seoul | |
| Korea, Republic of | Novartis Investigative Site | Seoul | |
| Korea, Republic of | Novartis Investigative Site | Suwon | |
| Korea, Republic of | Novartis Investigative Site | Taegu | |
| Korea, Republic of | Novartis Investigative Site | Wonju | Gangwon-Do |
| Lebanon | Novartis Investigative Site | Beirut | |
| Lebanon | Novartis Investigative Site | Beirut | |
| Lebanon | Novartis Investigative Site | Beirut | |
| Lebanon | Novartis Investigative Site | El Chouf | LBN |
| Lebanon | Novartis Investigative Site | Jbeil | |
| Lebanon | Novartis Investigative Site | Saida | |
| Malaysia | Novartis Investigative Site | Alor Setar | Kedah |
| Malaysia | Novartis Investigative Site | Johor Bahru | |
| Malaysia | Novartis Investigative Site | Kota Bahru | Kelantan |
| Malaysia | Novartis Investigative Site | Kuala Lumpur | |
| Malaysia | Novartis Investigative Site | Pulau Pinang | Penang |
| Mexico | Novartis Investigative Site | Aguascalientes | |
| Mexico | Novartis Investigative Site | Culiacán | Sinaloa SN |
| Mexico | Novartis Investigative Site | Mexico | Distrito Federal |
| Mexico | Novartis Investigative Site | Mexico | Distrito Federal |
| Mexico | Novartis Investigative Site | Mexico | Distrito Federal |
| Mexico | Novartis Investigative Site | San Luis Potosi | |
| Mexico | Novartis Investigative Site | San Luis Potosi | |
| Mexico | Novartis Investigative Site | Xalapa | |
| Mexico | Novartis Investigative Site | Xalapa | |
| Morocco | Novartis Investigative Site | Casablanca | |
| Morocco | Novartis Investigative Site | Marrakech | |
| Morocco | Novartis Investigative Site | Rabat | |
| Netherlands | Novartis Investigative Site | Amsterdam | |
| Netherlands | Novartis Investigative Site | Groningen | |
| Netherlands | Novartis Investigative Site | Leiderdorp | |
| Netherlands | Novartis Investigative Site | Sneek | |
| Netherlands | Novartis Investigative Site | Venlo | |
| Netherlands | Novartis Investigative Site | Zwolle | |
| Norway | Novartis Investigative Site | Hønefoss | |
| Norway | Novartis Investigative Site | Oslo | |
| Norway | Novartis Investigative Site | Skien | |
| Panama | Novartis Investigative Site | Panama | |
| Panama | Novartis Investigative Site | Panama City | |
| Panama | Novartis Investigative Site | San Jose De David | Panamá |
| Philippines | Novartis Investigative Site | Angeles City | Pampanga |
| Philippines | Novartis Investigative Site | Baguio City | Baguio |
| Philippines | Novartis Investigative Site | Cagayan De Oro City | Cagayan |
| Philippines | Novartis Investigative Site | Cebu City | Cebu |
| Philippines | Novartis Investigative Site | Davao City | Davao |
| Philippines | Novartis Investigative Site | Manila | Metro Manila |
| Philippines | Novartis Investigative Site | Quezon City | Manila |
| Romania | Novartis Investigative Site | Bucharest | |
| Romania | Novartis Investigative Site | Bucharest | |
| Romania | Novartis Investigative Site | Buzau | |
| Romania | Novartis Investigative Site | Cluj | Napoca |
| Romania | Novartis Investigative Site | Cluj-Napoca | |
| Romania | Novartis Investigative Site | Focsani | |
| Romania | Novartis Investigative Site | Lasi | |
| Romania | Novartis Investigative Site | Timisoara | |
| Russian Federation | Novartis Investigative Site | Kazan | |
| Russian Federation | Novartis Investigative Site | Kemerovo | |
| Russian Federation | Novartis Investigative Site | Krasnodar | |
| Russian Federation | Novartis Investigative Site | Moscow | |
| Russian Federation | Novartis Investigative Site | Moscow | |
| Russian Federation | Novartis Investigative Site | Novosibirsk | |
| Russian Federation | Novartis Investigative Site | Ryazan | |
| Russian Federation | Novartis Investigative Site | S-Petersburg | |
| Russian Federation | Novartis Investigative Site | Saint Petersburg | |
| Russian Federation | Novartis Investigative Site | Saratov | |
| Russian Federation | Novartis Investigative Site | Saratov | |
| Russian Federation | Novartis Investigative Site | St. Petersburg | |
| Russian Federation | Novartis Investigative Site | St.-Petersburg | |
| Russian Federation | Novartis Investigative Site | Stavropol | |
| Russian Federation | Novartis Investigative Site | Tyumen | |
| Russian Federation | Novartis Investigative Site | Ulyanovsk | |
| Russian Federation | Novartis Investigative Site | Vladivostok | |
| Russian Federation | Novartis Investigative Site | Volgograd | |
| Saudi Arabia | Novartis Investigative Site | Al Ahsa | |
| Saudi Arabia | Novartis Investigative Site | Dammam | |
| Saudi Arabia | Novartis Investigative Site | Dammam | |
| Saudi Arabia | Novartis Investigative Site | Khamis Mushayt | |
| Saudi Arabia | Novartis Investigative Site | Riyadh | |
| South Africa | Novartis Investigative Site | Bloemfontein | |
| South Africa | Novartis Investigative Site | Cape Town | |
| South Africa | Novartis Investigative Site | Cape Town | |
| South Africa | Novartis Investigative Site | Durban | Kwa-Zulu Natal |
| South Africa | Novartis Investigative Site | Rivonia | |
| Spain | Novartis Investigative Site | Alicante | Comunidad Valenciana |
| Spain | Novartis Investigative Site | Barakaldo | Pais Vasco |
| Spain | Novartis Investigative Site | Barcelona | |
| Spain | Novartis Investigative Site | Barcelona | Catalunya |
| Spain | Novartis Investigative Site | Barcelona | Cataluña |
| Spain | Novartis Investigative Site | Cordoba | |
| Spain | Novartis Investigative Site | Las Palmas de Gran Canaria | Las Palmas De G.C |
| Spain | Novartis Investigative Site | Leon | |
| Spain | Novartis Investigative Site | Majadahonda | Madrid |
| Spain | Novartis Investigative Site | Mallorca | Islas Baleares |
| Spain | Novartis Investigative Site | Merida | Extremadura |
| Spain | Novartis Investigative Site | Murcia | |
| Spain | Novartis Investigative Site | Tarragona | Catalunya |
| Sweden | Novartis Investigative Site | Göteborg | |
| Sweden | Novartis Investigative Site | Helsingborg | |
| Sweden | Novartis Investigative Site | Karlshamn | |
| Sweden | Novartis Investigative Site | Linkoping | |
| Sweden | Novartis Investigative Site | Malmö | |
| Sweden | Novartis Investigative Site | Trollhättan | |
| Switzerland | Novartis Investigative Site | Basel | |
| Switzerland | Novartis Investigative Site | Bruderholz | |
| Switzerland | Novartis Investigative Site | Zuerich | |
| Taiwan | Novartis Investigative Site | Lin-Kou | |
| Taiwan | Novartis Investigative Site | Taichung | |
| Taiwan | Novartis Investigative Site | Tainan | |
| Taiwan | Novartis Investigative Site | Taipei | |
| Taiwan | Novartis Investigative Site | Taipei | |
| Taiwan | Novartis Investigative Site | Taipei | |
| Thailand | Novartis Investigative Site | Bangkok | |
| Thailand | Novartis Investigative Site | Bangkok | |
| Thailand | Novartis Investigative Site | Chiang Mai | |
| Thailand | Novartis Investigative Site | Khon Kaen | THA |
| Thailand | Novartis Investigative Site | Muang | |
| Thailand | Novartis Investigative Site | Muang | |
| Thailand | Novartis Investigative Site | Muang | |
| Tunisia | Novartis Investigative Site | Monastir | |
| Tunisia | Novartis Investigative Site | Sousse | |
| Tunisia | Novartis Investigative Site | Tunis | |
| Tunisia | Novartis Investigative Site | Tunis | |
| Tunisia | Novartis Investigative Site | Tunis | |
| Turkey | Novartis Investigative Site | Ankara | |
| Turkey | Novartis Investigative Site | Ankara | |
| Turkey | Novartis Investigative Site | Bursa | |
| Turkey | Novartis Investigative Site | Bursa | |
| Turkey | Novartis Investigative Site | Diskapi / Ankara | |
| Turkey | Novartis Investigative Site | Haydarpasa/Istanbul | |
| Turkey | Novartis Investigative Site | Istanbul | |
| Turkey | Novartis Investigative Site | Meselik / Eskisehir | |
| Turkey | Novartis Investigative Site | Pendik / Istanbul | |
| Turkey | Novartis Investigative Site | Sivas | |
| United Arab Emirates | Novartis Investigative Site | Abu Dhabi | |
| United Arab Emirates | Novartis Investigative Site | Al Ain | |
| United Arab Emirates | Novartis Investigative Site | Dubai | |
| United Arab Emirates | Novartis Investigative Site | Dubai | |
| United Kingdom | Novartis Investigative Site | Bradford | West Yorkshire |
| United Kingdom | Novartis Investigative Site | Chesterfield | Yorkshire |
| United Kingdom | Novartis Investigative Site | Chesterfield | |
| United Kingdom | Novartis Investigative Site | Edgbaston | Birmingham |
| United Kingdom | Novartis Investigative Site | Herts | Yorkshire |
| United Kingdom | Novartis Investigative Site | Stockton on Tees | Cleveland |
| United Kingdom | Novartis Investigative Site | Telford | |
| United Kingdom | Novartis Investigative Site | Uxbridge | |
| United Kingdom | Novartis Investigative Site | Wakefield | |
| United Kingdom | Novartis Investigative Site | York | |
| United States | Novartis Investigative Site | Chicago | Illinois |
| United States | Novartis Investigative Site | Cincinnati | Ohio |
| United States | Novartis Investigative Site | Dallas | Texas |
| United States | Novartis Investigative Site | Detroit | Michigan |
| United States | Novartis Investigative Site | Detroit | Michigan |
| United States | Novartis Investigative Site | Indianapolis | Indiana |
| United States | Novartis Investigative Site | Jackson | Mississippi |
| United States | Novartis Investigative Site | Kansas City | Kansas |
| United States | Novartis Investigative Site | Nashville | Tennessee |
| United States | Novartis Investigative Site | New Orleans | Louisiana |
| United States | Novartis Investigative Site | New Orleans | Louisiana |
| United States | Novartis Investigative Site | New York | New York |
| United States | Novartis Investigative Site | San Diego | California |
| United States | Novartis Investigative Site | San Francisco | California |
| United States | Novartis Investigative Site | Stony Brook | New York |
| Vietnam | Novartis Investigative Site | Ho Chi Minh | |
| Vietnam | Novartis Investigative Site | Ho Chi Minh City | |
| Vietnam | Novartis Investigative Site | Ho Chi Minh City |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States, Vietnam, Algeria, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Ecuador, Egypt, Germany, Greece, Guatemala, India, Indonesia, Israel, Japan, Jordan, Korea, Republic of, Lebanon, Malaysia, Mexico, Morocco, Netherlands, Norway, Panama, Philippines, Romania, Russian Federation, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates, United Kingdom,
Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlström U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May;17(5):527-33. doi: 10.1002/ejhf.262. Epub 2015 Mar 10. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of patients with different characteristics of heart faliure (HF) at hospitalization | From admission to discharge of the patient's index hospitalization (minimum 24 hours) | ||
| Primary | Percentage of patients who die during the index hospitalization | From admission to discharge of the patient's index hospitalization (minimum 24 hours) | ||
| Primary | Percentage of patients who die during the follow-up period post-discharge | up to 3 years | ||
| Primary | Percentage of patients who are re-hospitalized by primary re-hospitalization reason (Cardiovascular and non-Cardiovascular) | up to 3 years | ||
| Primary | Number of patients with different characteristics of post-discharge patient management | up to 3 years | ||
| Primary | Healthcare Resource Utilization assessed by number of patients with re-hospitalizations | up to 3 years | ||
| Secondary | Health-related Quality of life (HRQoL) based on patient reported data as measured by EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ) questionnaires | up to 3 years | ||
| Secondary | Caregiver burden based on Caregiver Burden Questionnaire -Heart Failure (CBQ-HF) and Work Productivity and Activity Impairment (WPAI) questionnaires | up to 3 years | ||
| Secondary | Correlation ratio between practice patterns and outcomes | up to 3 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
| Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
| Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
| Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
| Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
| Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
| Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
| Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
| Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
| Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
| Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
| Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
| Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
| Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
| Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
| Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
| Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
| Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
| Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 |